Date Published

October 20, 2021

Updated For

ALS PCS Version 5.2


From your 2021 MCME COVID-19 Considerations precourse module:

Remember that the age condition of <50 years for administration of Epinephrine IM DOES NOT apply to the Moderate to Severe Allergic Reaction Medical Directive.  This age restriction only applies for the Bronchoconstrictive Medical Directive COVID-19 Considerations.

For more information and rationale for  COVID-19 practice considerations, check out the COVID-19 Considerations module on the PPO from your 2021 MCME precourse.


Additional Resources:

No additional resources available for this #SWORBHPTip.

Share this tip with others:

Select a platform: